Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation

Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation

Blockade of the human epidermal growth factor receptor 3 (HER3) and of the downstream phosphatidylinositide 3-kinase (PI3K)/AKT pathway is a prerequisite for overcoming drug resistance and to develop novel treatments for cancers that are not eligible for the currently approved targeted therapies. T...

Full description

Bibliographic Details
Main Authors: Yassamine Lazrek, Olivier Dubreuil, Véronique Garambois, Nadège Gaborit, Christel Larbouret, Christophe Le Clorennec, Gaelle Thomas, Wilhem Leconet, Marta Jarlier, Martine Pugnière, Nadia Vié, Bruno Robert, Céline Monnet, Khalil Bouayadi, Hakim Kharrat, Philippe Mondon, André Pèlegrin, Thierry Chardès
Format: Article
Language:English
Published: Elsevier 2013-03-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558613800620

Internet

http://www.sciencedirect.com/science/article/pii/S1476558613800620

Similar Items